Analysis of the Emerging Disease Landscape - COVID-19 - April 2020

Analysis of the Emerging Disease Landscape - COVID-19 - April 2020

Summary

The epidemiology of COVID-19 is rapidly evolving and a number of companies have begun to invest in this space. The absence of proven therapeutic options and the lack of a vaccine to protect against infection has led to a race to develop effective interventions. A range of players - from pharma and biotech firms to academic institutions and government agencies - have thrown their hats in the ring.

Scope

  • Global epidemiology metrics and trends
  • Snapshot of epidemiological trends to date in the top three most-affected countries
  • An overview of the pipeline for antivirals and vaccines
  • Summary of available efficacy data
  • An assessment of the clinical trials landscape by phase, sponsor type, geography, and other key attributes
  • Highlights in deal-making trends, particularly public-private partnerships
  • Spotlight on social media coverage
Reasons to Buy
  • Understand the global epidemiology of COVID-19
  • Obtain a snapshot of epidemiological trends to date in the top three most-affected countries
  • Access an overview of the pipeline for therapeutics and vaccines
  • Stay up to date on available efficacy data for pipeline-stage products
  • View the clinical trials landscape by across key attributes
  • Get up to speed on highlights in deal-making trends, particularly public-private partnerships
  • Monitor top trends in social media coverage


1. Executive Summary
2. Disease Background
3. Epidemiology
4. PipelineOverview
5. Clinical Trials
6. Deal-Making Trends
7. Social Media Trends
8. Key Findings
9. Appendix
10. About GlobalData

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings